Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

1 Pharmaceutical Stock Set to Rebound in 2026

TheMotleyFool

0 0

1 Pharmaceutical Stock Set to Rebound in 2026: https://g.foolcdn.com/editorial/images/852584/woman-injecting-self-in-arm-with-a-glp-1-injector-pen.jpg

2025 was a miserable year to own Novo Nordisk (NYSE: NVO) stock.

Shares of the Danish pharmaceuticals giant and inventor of Wegovy and Ozempic crashed 40% last year as the company steadily lost market share to rivals such as Eli Lilly (NYSE: LLY), which has competing Mounjaro and Zepbound drugs, and Novo Nordisk's earnings fell in tandem. Novo Nordisk earned $6.53 in the first quarter of the year. By the third quarter, earnings had shrunk nearly 30% to just $4.50 per share.

Image source: Getty Images.

Source Fool.com

Like: 0

NVO

Share